RIG-I recognizes metabolite-capped RNAs as signaling ligands.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
25 08 2023
Historique:
accepted: 12 06 2023
received: 06 10 2022
medline: 28 8 2023
pubmed: 16 6 2023
entrez: 16 6 2023
Statut: ppublish

Résumé

The innate immune receptor RIG-I recognizes 5'-triphosphate double-stranded RNAs (5' PPP dsRNA) as pathogenic RNAs. Such RNA-ends are present in viral genomes and replication intermediates, and they activate the RIG-I signaling pathway to produce a potent interferon response essential for viral clearance. Endogenous mRNAs cap the 5' PPP-end with m7G and methylate the 2'-O-ribose to evade RIG-I, preventing aberrant immune responses deleterious to the cell. Recent studies have identified RNAs in cells capped with metabolites such as NAD+, FAD and dephosphoCoA. Whether RIG-I recognizes these metabolite-capped RNAs has not been investigated. Here, we describe a strategy to make metabolite-capped RNAs free from 5' PPP dsRNA contamination, using in vitro transcription initiated with metabolites. Mechanistic studies show that metabolite-capped RNAs have a high affinity for RIG-I, stimulating the ATPase activity at comparable levels to 5' PPP dsRNA. Cellular signaling assays show that the metabolite-capped RNAs potently stimulate the innate antiviral immune response. This demonstrates that RIG-I can tolerate diphosphate-linked, capped RNAs with bulky groups at the 5' RNA end. This novel class of RNAs that stimulate RIG-I signaling may have cellular roles in activating the interferon response and may be exploited with proper functionalities for RIG-I-related RNA therapeutics.

Identifiants

pubmed: 37326006
pii: 7199333
doi: 10.1093/nar/gkad518
pmc: PMC10450190
doi:

Substances chimiques

DEAD Box Protein 58 EC 3.6.4.13
DEAD-box RNA Helicases EC 3.6.4.13
Interferons 9008-11-1
Ligands 0
RNA Caps 0
RNA, Double-Stranded 0
RNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

8102-8114

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM118086
Pays : United States

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
J Virol. 2009 Aug;83(16):8276-81
pubmed: 19494017
J Virol. 2006 Sep;80(17):8362-70
pubmed: 16912287
Immunity. 2015 Jul 21;43(1):41-51
pubmed: 26187414
J Biol Chem. 1997 Nov 28;272(48):30147-53
pubmed: 9374495
Acc Chem Res. 2021 Nov 2;54(21):4012-4023
pubmed: 34677064
Nucleic Acids Res. 2003 Feb 1;31(3):e8
pubmed: 12560511
Nat Rev Microbiol. 2011 Dec 05;10(1):51-65
pubmed: 22138959
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7768-73
pubmed: 19416889
Eur J Biochem. 2003 Apr;270(7):1458-65
pubmed: 12654001
Elife. 2018 Dec 12;7:
pubmed: 30526856
Mol Cell. 2018 Oct 18;72(2):355-368.e4
pubmed: 30270105
Virology. 2002 Jul 20;299(1):122-32
pubmed: 12167347
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):596-601
pubmed: 26733676
Nature. 2016 Jul 21;535(7612):444-7
pubmed: 27383794
RNA. 2009 Dec;15(12):2340-50
pubmed: 19850911
Cell Rep. 2019 Feb 19;26(8):2019-2027.e4
pubmed: 30784585
J Virol. 2017 Sep 27;91(20):
pubmed: 28768856
J Immunol. 2005 Sep 1;175(5):2851-8
pubmed: 16116171
Cell. 2010 Feb 5;140(3):397-408
pubmed: 20144762
Transl Res. 2017 Dec;190:51-60
pubmed: 28917654
Nat Immunol. 2010 Jan;11(1):63-9
pubmed: 19915568
EMBO J. 2022 May 16;41(10):e109782
pubmed: 35437807
Nat Chem Biol. 2009 Dec;5(12):879-81
pubmed: 19820715
Nature. 2014 Oct 16;514(7522):372-375
pubmed: 25119032
Nature. 2021 Mar;591(7850):477-481
pubmed: 33627873
Nature. 2011 Sep 25;479(7373):423-7
pubmed: 21947008
Nucleic Acids Res. 2016 Jan 29;44(2):896-909
pubmed: 26612866
Nat Immunol. 2004 Jul;5(7):730-7
pubmed: 15208624
Nature. 2018 Aug;560(7717):238-242
pubmed: 30046113
Nucleic Acids Res. 2019 Nov 18;47(20):e130
pubmed: 31504804
Mol Cell. 2013 Sep 12;51(5):573-83
pubmed: 23993742
J Virol. 2005 Mar;79(5):2689-99
pubmed: 15708988
Virology. 1993 Nov;197(1):265-73
pubmed: 8212562
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6972-6
pubmed: 7518923
Nature. 2015 Mar 19;519(7543):374-7
pubmed: 25533955
Cell. 2017 Mar 9;168(6):1015-1027.e10
pubmed: 28283058
RNA. 1999 Sep;5(9):1268-72
pubmed: 10496227

Auteurs

Brandon D Schweibenz (BD)

Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.
Graduate School of Biomedical Sciences at the Robert Wood Johnson Medical School of Rutgers University, USA.

Mihai Solotchi (M)

Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.
Graduate School of Biomedical Sciences at the Robert Wood Johnson Medical School of Rutgers University, USA.

Pranita Hanpude (P)

Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.

Swapnil C Devarkar (SC)

Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.
Graduate School of Biomedical Sciences at the Robert Wood Johnson Medical School of Rutgers University, USA.

Smita S Patel (SS)

Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH